Delving into the Latest Updates on Nanjing Jisheng Aoma Biopharmaceutical Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Neoplasms

Otorhinolaryngologic Diseases

Cytokines

Trispecific antibody

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Trispecific antibody	2
Antibody	1
Cytokines	1
Bispecific antibody	1
Fusion protein	1

Top 5 Target	Count

IFN α x IL-2	1
CD molecules x CD16	1
PDL1(Programmed death-ligand 1)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

3

Preclinical

Phase 1

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

IAMA-001	Rhinitis, Allergic, Seasonal More	Phase 1
IAMA-005 ( IFN α x IL-2 )	Neoplasms More	Preclinical
IAMA-002	Respiratory Diseases More	Preclinical
IAMA-004	Respiratory Diseases More	Preclinical
WO2023217216 ( CD molecules x CD16 )Patent Mining	Leukocyte Disorders More	Discovery